Since multiple myeloma cells also express high levels of Kv1.3 [22] (also see https://www.proteinatlas.org/ENSG00000177272-KCNA3/single+cell+type (accessed on 25 February 2022) for RPMI-8226) and are characterized by high intracellular ROS levels [23], here we investigated the effects of these novel Kv1.3 inhibitors on different multiple myeloma cell lines as well as in patient-derived primary multiple myeloma cells. This evidence concerns the gene KCNA3 and plasma cell myeloma.